Show simple item record

dc.contributor.authorFindlay, M
dc.contributor.authorVon Minckwitz, G
dc.contributor.authorWardley, Andrew M
dc.date.accessioned2009-04-02T15:59:55Z
dc.date.available2009-04-02T15:59:55Z
dc.date.issued2008-02
dc.identifier.citationEffective oral chemotherapy for breast cancer: pillars of strength. 2008, 19 (2):212-22 Ann. Oncol.en
dc.identifier.issn1569-8041
dc.identifier.pmid18006898
dc.identifier.doi10.1093/annonc/mdm285
dc.identifier.urihttp://hdl.handle.net/10541/59154
dc.description.abstractTraditionally, anticancer therapy has been dominated by intravenous drug therapy. However, oral agents provide an attractive approach to chemotherapy and use of oral treatments is increasing. We discuss the benefits and challenges of oral chemotherapy from the perspectives of patients, healthcare providers and healthcare funders. Important issues include patient preference, efficacy, compliance, bioavailability, reimbursement, use in special patient populations, financial and staff time savings and flexibility of dosing. We review data for traditional oral agents (e.g. cyclophosphamide, methotrexate), newer oral chemotherapies (e.g. capecitabine), oral formulations of traditionally intravenous agents (e.g. vinorelbine, idarubicin) and new biologic agents under evaluation in breast cancer (e.g. tyrosine kinase inhibitors). Lastly, we review studies of all-oral combination regimens. The wealth of data available and the increasing use of oral agents in breast cancer suggest that many of the concerns and perceptions about oral therapy, including efficacy and bioavailability, have been overcome, and that oral therapy will play a major role in breast cancer management in the future in both the metastatic and adjuvant settings.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectAnticancer Therapyen
dc.subject.meshAdministration, Oral
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBreast Neoplasms
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMastectomy
dc.subject.meshPrognosis
dc.subject.meshSensitivity and Specificity
dc.subject.meshSurvival Analysis
dc.subject.meshTreatment Outcome
dc.titleEffective oral chemotherapy for breast cancer: pillars of strength.en
dc.typeArticleen
dc.contributor.departmentFaculty of Medical & Health Sciences, University of Auckland, Auckland, New Zealand. mp.findlay@auckland.ac.nzen
dc.identifier.journalAnnals of Oncologyen
html.description.abstractTraditionally, anticancer therapy has been dominated by intravenous drug therapy. However, oral agents provide an attractive approach to chemotherapy and use of oral treatments is increasing. We discuss the benefits and challenges of oral chemotherapy from the perspectives of patients, healthcare providers and healthcare funders. Important issues include patient preference, efficacy, compliance, bioavailability, reimbursement, use in special patient populations, financial and staff time savings and flexibility of dosing. We review data for traditional oral agents (e.g. cyclophosphamide, methotrexate), newer oral chemotherapies (e.g. capecitabine), oral formulations of traditionally intravenous agents (e.g. vinorelbine, idarubicin) and new biologic agents under evaluation in breast cancer (e.g. tyrosine kinase inhibitors). Lastly, we review studies of all-oral combination regimens. The wealth of data available and the increasing use of oral agents in breast cancer suggest that many of the concerns and perceptions about oral therapy, including efficacy and bioavailability, have been overcome, and that oral therapy will play a major role in breast cancer management in the future in both the metastatic and adjuvant settings.


This item appears in the following Collection(s)

Show simple item record